6Q6L

Crystal structure of recombinant human beta-glucocerebrosidase in complex with adamantyl-cyclophellitol inhibitor (ME656)

Summary for 6Q6L

• Entry DOI: 10.2210/pdb6q6l/pdb
• Related: 6Q6K
• Descriptor: Glucosylceramidase, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (8 entities in total)
• Functional Keywords: hydrolase, retaining beta-glucosidase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 116625.85

Authors

Rowland, R.J.,Davies, G.J. (deposition date: 2018-12-11, release date: 2019-03-27, Last modification date: 2024-01-24)

Primary citation

Artola, M.,Kuo, C.L.,Lelieveld, L.T.,Rowland, R.J.,van der Marel, G.A.,Codee, J.D.C.,Boot, R.G.,Davies, G.J.,Aerts, J.M.F.G.,Overkleeft, H.S.
Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish.
J.Am.Chem.Soc., 141:4214-4218, 2019

PubMed Abstract: Gaucher disease is caused by inherited deficiency in glucocerebrosidase (GBA, a retaining β-glucosidase), and deficiency in GBA constitutes the largest known genetic risk factor for Parkinson's disease. In the past, animal models of Gaucher disease have been generated by treatment with the mechanism-based GBA inhibitors, conduritol B epoxide (CBE), and cyclophellitol. Both compounds, however, also target other retaining glycosidases, rendering generation and interpretation of such chemical knockout models complicated. Here we demonstrate that cyclophellitol derivatives carrying a bulky hydrophobic substituent at C8 are potent and selective GBA inhibitors and that an unambiguous Gaucher animal model can be readily generated by treatment of zebrafish with these.

PubMed: 30811188
DOI: 10.1021/jacs.9b00056

Experimental method

X-RAY DIFFRACTION (1.81 Å)